{"ticker": {"uuid": "2b9325f4-11a1-4bdb-9991-43c2335ed340", "symbol": "KPTI", "name": "Karyopharm Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "KPTI5813817 Bond Risk Profile", "summary": "This article provides a bond risk profile for Karyopharm Therapeutics Inc.'s 6.0% bond, KPTI5813817, due May 13, 2029. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliability. ", "url": "https://www.tradingview.com/symbols/FINRA-KPTI5813817/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-14T03:11:42", "published_display": "14 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI5813817 Bond Profile \u2014 Key Metrics", "summary": "This article provides a bond profile for Karyopharm Therapeutics Inc.'s KPTI5813817 bond, detailing key metrics such as a 6.0% coupon rate and a May 13, 2029 maturity date. The company, founded in 2008, is a commercial-stage pharmaceutical company focused on cancer and other dise", "url": "https://www.tradingview.com/symbols/FINRA-KPTI5813817/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-13T21:42:03", "published_display": "13 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE40Z3RWQmc1X0ZQMzRVQnJycEYxTmRSdkFwXzUxcEdja3VrM1d4ODBBSTVJRjFmRDJVcGtCMHZJQzdMSUVqWnVBTlUyZUoxaGJfVzM0VTE2emJCWmc?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:13:55+00:00", "published_display": "11 Jul 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16", "summary": "RBC Capital has reiterated its Buy rating for Karyopharm Therapeutics (KPTI.US), maintaining a target price of $16. This indicates the firm's continued positive outlook on the company's stock performance and valuation. The maintained ratings suggest that RBC Capital perceives ong", "url": "https://www.moomoo.com/news/post/72681903/rbc-capital-maintains-karyopharm-therapeutics-kptius-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-09T07:40:58", "published_display": "09 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Q2 2024 earnings summary", "summary": "Karyopharm Therapeutics (KPTI) reported a strong Q2 2024, achieving a net income of $23.8 million, a significant turnaround from a net loss in Q2 2023, primarily due to a non-cash gain on debt extinguishment. Total revenue grew to $42.8 million, driven by increased license and mi", "url": "https://quartr.com/events/karyopharm-therapeutics-inc-kpti-q2-2024_3PQWjohD", "source_name": "Quartr", "published_at": "2026-07-08T18:10:07", "published_display": "08 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Q4 2024 earnings summary", "summary": "Karyopharm Therapeutics (KPTI) reported total revenue of $145.2M in 2024, with U.S. XPOVIO net product revenue at $112.8M, and a reduced net loss of $76.4M. The company is advancing pivotal phase III clinical trials with key data readouts expected in 2025 and 2026, and anticipate", "url": "https://quartr.com/events/karyopharm-therapeutics-inc-kpti-q4-2024_3PQWjfnc", "source_name": "Quartr", "published_at": "2026-07-08T17:40:33", "published_display": "08 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Q1 2025 earnings summary", "summary": "Karyopharm Therapeutics released its Q1 2025 earnings summary, highlighting progress in its Phase 3 SENTRY trial for myelofibrosis, which passed futility analysis and is expected to complete enrollment by mid-2025 with top-line data anticipated late 2025/early 2026. Despite a dec", "url": "https://quartr.com/events/karyopharm-therapeutics-inc-kpti-q1-2025_3PQWf4fK", "source_name": "Quartr", "published_at": "2026-07-08T17:40:32", "published_display": "08 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics faces a data setback as investors weigh late-stage cancer pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPVHBkdWpxcWVVMnMzYU1ZM2tabEZ2ZXhSQ3hlcXJFYmtuNWR2WEdjMUJRZ2sxOHhSMkllVWdmd3Ziem95OHpuSFJ1bzlQTEpxMFhLUkJqZy1idkQtM0w0dFhjVUFlOFFIUFduRGZ4YS16Q08wX3hrNEk3S2JVaFdXUWF3VVlqVDk1dmZrUnJyR3NGRkM4TTVVcW1rcUxzOVJwcDl5WXNITlBNMmdsMDN2WFNjRktVYnVCcVU1NDVQanBNdWZkM2hPR2pSTWZ3Zw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T19:37:26+00:00", "published_display": "07 Jul 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI - Karyopharm Therapeutics Inc Latest SEC Filings", "summary": "This page provides the latest SEC filings for Karyopharm Therapeutics Inc (KPTI), along with a comprehensive overview of its financial data, market performance metrics, insider transactions, and analyst recommendations. Key figures included are market capitalization, sales, incom", "url": "https://finviz.com/stock?t=KPTI&p=d&ty=lf&r=m6&page=30", "source_name": "Finviz", "published_at": "2026-07-06T16:42:39", "published_display": "06 Jul 2026 16:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Karyopharm Therapeutics Inc. announced it granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees on June 30, 2026. These RSU awards, made under the Company's 2022 Inducement Stock Incentive Plan, are material inducements for their employment as ", "url": "https://investors.karyopharm.com/2026-07-01-Karyopharm-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4", "source_name": "Karyopharm", "published_at": "2026-07-06T06:11:28", "published_display": "06 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm gives 4 new hires stock awards vesting over 3 years", "summary": "Karyopharm Therapeutics (Nasdaq: KPTI) granted 1,649 restricted stock units (RSUs) to four new employees on June 30, 2026, under its 2022 Inducement Stock Incentive Plan. These RSUs, designed to induce employment, will vest over three years, with 33 1/3% vesting annually, conting", "url": "https://www.stocktitan.net/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-gnqqzmakh8pq.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:09", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI - Karyopharm Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial snapshot of Karyopharm Therapeutics Inc (KPTI), including its stock performance, key financial metrics, and volatility data. It lists various ratios, growth rates, insider and institutional ownership, and analyst recommendations. The dat", "url": "https://finviz.com/stock?t=KPTI&p=d&r=m6&ty=ocv&ov=chain_date&e=2026-08-21", "source_name": "Finviz", "published_at": "2026-07-01T14:39:58", "published_display": "01 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI - Karyopharm Therapeutics Inc Dividends", "summary": "This article provides detailed financial and stock performance data for Karyopharm Therapeutics Inc. (KPTI). It includes various financial metrics such as market cap, income, sales, EPS, and insider ownership, alongside stock performance indicators over different periods. The dat", "url": "https://finviz.com/stock?t=KPTI&b=2&p=m&ty=dv", "source_name": "Finviz", "published_at": "2026-07-01T02:39:09", "published_display": "01 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark", "summary": "Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to the Russell Small Cap Comp Growth Benchmark, as announced by S&P Capital IQ. The company is a commercial-stage pharmaceutical firm focused on developing and commercializing drugs that inhibit nuclear export for cance", "url": "https://www.marketscreener.com/news/karyopharm-therapeutics-inc-nasdaqgs-kpti-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd81f623", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:40:24", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Index", "summary": "Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), a commercial-stage pharmaceutical company, has been added to the Russell 2000 Index. The company focuses on discovering, developing, and commercializing drugs targeting nuclear export for cancer treatment, with its lead asset XPOVIO (", "url": "https://www.marketscreener.com/news/karyopharm-therapeutics-inc-nasdaqgs-kpti-added-to-russell-2000-index-ce7f5fdfda8dfe26", "source_name": "marketscreener.com", "published_at": "2026-06-29T18:40:24", "published_display": "29 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Growth Benchmark", "summary": "Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to several Russell indices, including the Russell 2000 Growth Benchmark, Russell Small Cap Comp Growth Benchmark, Russell 2500 Growth Benchmark, and Russell 2000 Index. This inclusion follows a period of news regarding ", "url": "https://www.marketscreener.com/news/karyopharm-therapeutics-inc-nasdaqgs-kpti-added-to-russell-2000-growth-benchmark-ce7f5fdede8fff2c", "source_name": "marketscreener.com", "published_at": "2026-06-29T10:40:24", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000E Index", "summary": "Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to the Russell 3000E Index. The company is a commercial-stage pharmaceutical firm focused on developing drugs against nuclear export for cancer treatment. Its lead asset, XPOVIO (selinexor), is used for multiple myeloma", "url": "https://www.marketscreener.com/news/karyopharm-therapeutics-inc-nasdaqgs-kpti-added-to-russell-3000e-index-ce7f5fdedd8ff22d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:41:41", "published_display": "29 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Karyopharm Therapeutics Inc. \u2013 NASDAQ:KPTI", "summary": "This article provides access to the enterprise value to EBITDA forward data for Karyopharm Therapeutics Inc. (NASDAQ: KPTI) on the TradingView platform. It highlights the company's financial overview within the pharmaceuticals sector, emphasizing data sources and intellectual pro", "url": "https://www.tradingview.com/symbols/NASDAQ-KPTI/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:39:20", "published_display": "28 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Karyopharm Therapeutics Inc. \u2013 NASDAQ:KPTI", "summary": "This article provides the \"Price to sales forward\" metric for Karyopharm Therapeutics Inc. (NASDAQ: KPTI). It is a short piece that simply presents this specific financial data point without further analysis or commentary. The content indicates \"No trades\" at the time of viewing,", "url": "https://www.tradingview.com/symbols/NASDAQ-KPTI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:09:24", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics, Inc. Actuals & Estimates (NASDAQ:KPTI)", "summary": "This article provides an overview of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) stock, including its current price, market capitalization, and analyst forecasts. It details historical stock performance, earnings per share, and revenue figures, along with upcoming earnings dates.", "url": "https://www.tradingview.com/symbols/NASDAQ-KPTI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:35", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25K0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Karyopharm Therapeutics, Inc. (25K0) stock, including analyst price targets and ratings. It also offers key financial metrics such as EPS, revenue, net income, and EBITDA, along with frequently asked questions about the company's stock perform", "url": "https://www.tradingview.com/symbols/DUS-25K0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:35", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a comprehensive forecast for Karyopharm Therapeutics Inc. (KPTI) stock, including analyst price targets, historical performance, and financial metrics. It details the company's recent stock movements, earnings reports, revenue, market capitalization, and vol", "url": "https://www.tradingview.com/symbols/NASDAQ-KPTI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:35", "published_display": "25 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOd2NPYkRxak5DWF9XRUJzMHYyN09ES2NSd0Jmd0J2eG1iN3ltS0xDVkJGUkJEVjFKU3ZQLUVCbkJnTzFPU1JaSEVHblRKeEFlSTlGMFVLanExdFdrZS1zWEM1WE5kdU1mQXFjdl9NMEVCNGRCeE1ETnFIOHJDRmNLMEZ6V1VUQmxUWGtFUmNNOFVCTWNDb0FESm84NVIzdkNlNV96M1lDOA?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell", "summary": "Karyopharm Therapeutics receives a reiterated Sell rating due to ongoing clinical and commercial challenges with its drug selinexor (Xpovio). Stagnant Xpovio revenues of $115 million, coupled with toxicity issues and competition, undermine growth and adoption. Recent Phase 3 tria", "url": "https://seekingalpha.com/article/4916153-karyopharm-xpovio-revenue-stagnation-and-toxicity-concerns-justify-sell", "source_name": "Seeking Alpha", "published_at": "2026-06-18T20:39:56", "published_display": "18 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc (KPTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Karyopharm Therapeutics Inc (KPTI), highlighting its current price momentum score, support and resistance levels, and various technical indicators and moving averages. The analysis suggests that KPTI is suitable for range-bound swing ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kpti/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:56", "published_display": "18 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Karyopharm Therapeutics Inc (KPTI)'s shareholder structure, including its major individual shareholders and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type (e.g., Hedge Fund, Inves", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kpti/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:17", "published_display": "18 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Karyopharm Therapeutics Inc (KPTI). It indicates that KPTI has distributed $0.00 in dividends over the past five years and lists several upcoming merger-related stock splits scheduled for February 24, 2025. T", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kpti/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:17", "published_display": "18 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Karyopharm stock", "summary": "Cantor Fitzgerald has reiterated an Overweight rating on Karyopharm Therapeutics (NASDAQ:KPTI), following discussions with management about the potential of selinexor in endometrial cancer maintenance. The firm highlighted the unmet need in this area and how existing data de-risk", "url": "https://m.uk.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-overweight-on-karyopharm-stock-93CH-4719513?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-09T13:09:56", "published_display": "09 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPbUI3dlBnUTFtcTNZQTJ1LU81eUZQM1JvVVZEOVc3UjdFSnlrcXJDdkttNnJOQndpb3lyLXF0Vldyd2w3a2I1aUtubmxoV3A4RXVheGI5eDdjbjZ2aUVKTmt0SGJrWmVjYWF0VUhVOEJUX0VCajFvZjdqX1R4SkwzaVBtNmNVM3RRTnJtZTNHc1k0N0lyWURLd2FWNXU4NzV3R1lGNi04TEhMVmJrcHl6SzdrcGE?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Karyopharm Therapeutics Inc. announced an inducement grant of 1,200 restricted stock units (RSUs) to a new employee, effective May 31, 2026. This grant was made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. The RSUs will vest over three years, cont", "url": "https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302786006.html", "source_name": "PR Newswire", "published_at": "2026-06-05T06:09:11", "published_display": "05 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026", "summary": "Karyopharm Therapeutics Inc. announced it will host a virtual fireside chat on June 8, 2026, featuring its senior management and Dr. Robert Coleman, a key opinion leader in endometrial cancer. The webcast, organized by Cantor, will discuss the company's progress and the Phase 3 X", "url": "https://investors.karyopharm.com/2026-06-03-Karyopharm-to-Participate-in-Webcast-Featuring-Endometrial-Cancer-Key-Opinion-Leader-on-June-8,-2026", "source_name": "Karyopharm", "published_at": "2026-06-03T22:39:34", "published_display": "03 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology", "summary": "Karyopharm Therapeutics announced it will present results from its Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis at ASCO 2026, with simultaneous publication in the Journal of Clinical Oncology. The trial demonstrated a rapid and nearly doubled rate of spleen", "url": "https://www.prnewswire.com/news-releases/karyopharm-to-present-results-from-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-in-late-breaking-oral-presentation-at-asco-2026-with-simultaneous-publication-in-the-journal-of-clinical-oncology-302788575.html", "source_name": "PR Newswire", "published_at": "2026-06-03T04:10:02", "published_display": "03 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/karyopharm-report-data-phase-3-152117570.html", "source_name": "MT Newswires", "published_at": "2026-06-02T15:21:17+00:00", "published_display": "02 Jun 2026 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAJBVV95cUxOQ3h3RDNiUDktQ1ZjLWJELUNHT29TejdCUTdqY2FSWE9MRFUtWnBOOUx5eGhzeXlJNnU1S3B5MjZfcDRsV09zem8tei1GMVBZZTVJc09ndzhkN2NkQUUtZEZqVlo0amw3WXBWT2pEZXRQYWJ4UUl3cjFtQ2lWOFdUdzF3QnZCLWpfYkt2WlNNZnBqczZZc2RKb3RGaGNVQno3ZFZSdlppYlpOcnEzUEhlUUVselNqWnZtYzBmTXI2ckhxOXFOaG1iSVRDV25hLTlhUzhGS3VmeXd3YlE0QnNwaHllMUdTQmxIWlNUcERHLU5RQzlHaEF5ZGVJS3UyZEtsMVExT01iNWJxSF9ldElGd2Z1UW9oRjdibTZYdQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAJBVV95cUxPUG1iOVpDSXZGSm1vR3QtZjA2Yl9DeWYxekFZcWlZdmVaTTQ0ZllUQWdicVZueXVGLW5BZmRYbEtxR2R3T1o2WXFweVhmWDZzSEdtbnJ0S0djNVlpclJOV2MwVWI4TE9vM3lfa2xZQnB6dldxX2c3bnlhZ2dmQVR6ZkFvUjhVNkVjdFBnem5aZEFYNXRoaFVWWmdGdVhSQ1BtV2JGZmlSSjFDU1hxVlBhV055RF9LTjQ3WVU5Z0czZUVNTjFwbUlrTTlSQlVUcWp6SS1leE9HRjBDUllhRTlVdnNscmF6VEVlaTdpemR3cnlXV3M5djQtRkZnYXJBSm1RS3JDbTJfUUVlZHYyRU1LU0ptLVU1RXMtQlFReDZYV0RYRzVKLXJvRkpqZFhNbm5n?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Quarterly Loss Deepens Reinforcing Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxQNHVSSm55NG1qaUVJT3lqVXlfV3dlZ25KMm5JYndWT3ZLRDlwNVlxSkhqV1BkSlhaNHpSSnM5MVR4V1NGckYwVFBWZ0xabTJ5OHBPTDhUZmhURGQxcFdXTV9UbF9WdmctQnE2bm9tQl9renY5RzJjRUl3ODc0TDlBdURkNHlRbXpPWFVOb2gtUTNfRDRLSFl0aVU0VXhaa01ILU1mTFdtUTVKSFVuQU8tM1N6ZUNIcnZHNVJYenZPdmYzajJ3UThyWExfUlZHYzBVRnVDMDR2ektLZzdVR0c5REQ0RmRQcnBHLU5rZDNCOFIzV2tiUDVvMXlzUEltT2NwUFcw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Karyopharm Therapeutics stock (US48666T1097): Analyst target lifted as biotech eyes growth in XPOVIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOZUZaNXVHUl9PY3cxdnllMnctMXQ1Wm1UOVBtVG9PbGZNSUJjTDgwUVN0UWtXTXc0dERYOWJyc3A3cUdmLWlnMzNVdmVwSUl4U0JIa0Z5c2gzQTJqOUhId05KNVlFWDhhNVpsbFR6VVZyYWk2XzVoT21JTTd3VGJKNXRyOEhKV1A5RzVvU1J5eVpVSDZEQ19xcmJ4dC1uS2FXa3NzN2lMWTRLMVA4VFluV3JnLU5LNTE4WkxFR2R4M2gxeGhE?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxONVR2YnVXRlRiQmE5djRVcmFFc2hYdlNXb0ZiUDBsNHN6M1EtMDh1U2M3ZGZCQ1AwSnJ0eHhLM3NyUnl5a3BpdkZ4bVUwbi0zX3pRdGxPdzBhU1ljbFBxTEJQNzNiNFpSUlRaamJ3YjJKQXlyQzBsMVF1WjlTaXA0aXNxZEJVVTkxQUZNU28xNWZSelhSdGxhSW5Tb21ObUkyVW5pd2xOTEw?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxNaENpTi1uUXdmb0VQa05EZlRXclZKZHdZUjAyZ2hfWVVNTFAxMEd3dDBnWFlsTEZqa1ZZMTUzbnFDQ21VLTZoR3VHVnk4NFVKNlZWU1lPS2VGV3BhVkpIVEdMeDFYMU9hSllxeENQamF5UVZpQ01qMUhzOFl6YnZ6aVVQcU9sdHd2SHpHaWkwb2MwcU5nVDk1a3JlZDNXa3VjMWlWYXJYcWcyZGhjemo1MGhINms5T1dKZFIyUzRWYzFhMjUyZW5YZXVhajBuZG5rSng1aE5oZFg4Tk5KRVA2LVhwZVN4S3h3VWc1Z3dfM0I2X2htNWR6VmpjY1dkZ2VUSkF4VHhjanhOekhGVWxfZDJJdklKOUdMSWUzU1NRVl9KOFVUQ1VFZlFDbw?oc=5", "source_name": "Karyopharm", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces $30 Million Private Placement with RA Capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPWXltbXltM2tBbm1QLUpWZmpQYXB2LS0wb1RhXzlwRl9YY2ZPTnpidGpOXzI2R2FNRk5MdDE1RWJtTlBhM3dDb3dwdWR5UW5RbERUMjlOTU9oQ0E5eHdmRnRkOEd0Ymx0RTF4R21IWkt2cFd0cmZDVmk4VkNmY0ViT1Uwby1WMzU1SVpyYW5oakFSdTRlLWtJQWMzaUx6UFloNzc5WDdzM25scmlQbVYwZTVPREZnQlBjcFNRekVn?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNX3FGRVM2RFFhQnNhVDdaekNuS25WcjUyaHNINWo5aXo3T0xuYTRjTnI3VG5hZ1NHQW9lOWdoRXlwUDhRX0duSTRxbVlhYXVja1lhSFl2R3hKd3hwNklKdEpqazRvR1Vmd3NFTmlFeFZrYXNxUG5UZkJzY3pCdnp6NnVfZ0paRDVFWUx0VV9VT1cwaUM2emFIRUZ4MDN3U1hXNEdrWnpZbnpKR0haWWVDVHQ5akhCM01rc1E?oc=5", "source_name": "Market source", "published_at": "2026-03-22T07:00:00+00:00", "published_display": "22 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc. Common Stock (KPTI) Stock Price Today: $10.34", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1rTE1WT2ZMOXpWQTM0eGRBUEhMRGZFb2ozVlV5bTlibWlZelBqQ3hjNDFaM181eHRaa2czdVh3MkY5WC1hM0xrVkhLVjZkYXhHaTBoMUNQTQ?oc=5", "source_name": "Gotrade", "published_at": "2026-02-14T22:17:35+00:00", "published_display": "14 Feb 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQMmhCbGxTaHktZ3ZqUXlldl9NYm5OX2FnMUNnVzNTblc3MTJvSWFLMmwxaFowX2tjajNONnhjQThEX1RiZGpEQWZMVDJ6d3BYYWNnZVd2cEJfV3hwbFZjYWtlRGc5Y2w0anR0Qlgxand6TlNhRWtBbXN0a0xXb1FiaDZoRV9aOHY0TmtfenNB?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How New Price Targets Are Shaping The Story For Karyopharm Therapeutics (KPTI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPU3dWU2RDT1VzeFV2eFFHWVVTazJLNlo1ckRHUkJoT2V5VzdaMWl4RWUxazZRZXBkQzk0aDZsVlY5TTY1MW9YOHFxb0xlOUxGaFV0MFI5b180b1VoM096X2pJNDZwWHltUGVXZ2YteXk4UnRMMGkxUDhaTFM0d0RTTElSTkZMRnNYN3Bwdw?oc=5", "source_name": "Market source", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOVG1PaEJkRDNERnE3NG1IQnhmZlktNkZ0NExpeTd5dkx0bGpHaWJ4OHcxczR4bEF2b3R3SnBqb1BncWY1bzZMOW9KYnN4OEd4THBJek1vb3hJZTBPWVItZTVHU1hERjh2azQ3cHhuV1NTT1FoZHBtNTY3QjBIYjZma1lTSVgwOVNSNTFDMEZXXy1ub2ZsUm44QWE4OEs3em41VF9kR2ZJTVJTWmRpQ1ZBVzVmY1o3M09KeHZCc055ZTB2MmRDOXd2eE8wQkR2ZzN5ejh0Ng?oc=5", "source_name": "Karyopharm", "published_at": "2025-11-03T08:00:00+00:00", "published_display": "03 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOaHVpMGIyUFdmY1poRjVoVXVIdlBXTmVBUGdNZHBsMVRQV19PYnVsTzFkdy0ySHJVZlptcmRpVm5TRTBEcUNPcWV1Qm1sZkphNWYyd0lYeGs2SERvSERwbVN6bTNKYTZfdUZLS2JibGdUQUd5ZU5Odkk5bVhLc2ljYUMzSEtpSFJsX2l0aC1qMjByWTYyQ2szWkJfUzNVQ0dzVkQyaDF5WE1ERzhySU1WRm1fQ1hzdEw5WEtWMDdtZzVldHBoTTl3RE5wcVZWVk0?oc=5", "source_name": "Karyopharm", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-14T07:00:00+00:00", "published_display": "14 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQb1JnLW5xMk85WWoyaDlfZjFrYU1PcDhaeHV5cW91LWhwdm9BTkx6ZktyRURPQ3ZaUVhLSndHVFRhbGhwTUhYVGw0b1F4UXdCX3dWUUZuZ2Q0TVVKNEtIcl9jMzRvMWhmQnViaVZSZktvUEY2QWRFeHp1SklQT0ZsVFVTQkRhN3R5NGRFX01HcVo2NkxPWExORWt0WU1xSTV1RTZ0azM0MTRuNGhLZng1ZDdjekk1Z05TQTJiSTNlY1p0dw?oc=5", "source_name": "Karyopharm", "published_at": "2025-01-02T08:00:00+00:00", "published_display": "02 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowJBVV95cUxNRkVEMzNuWlgtbjdPVXVmUzBRVXpFSHl1bHBONXROc2Z4RW12Q0tEaXNCbEpXeHRfZy1oZ0RraVJVVF82QVE5V2o0R3MyWktyM2xhV2hiajdDd01CTVBCdUJNdFQ2YkJIMEYyb1VId1N2SVJBb1lGcnpRalhyODFZMDZpXzRRWTdqVjI0X2h5LThiNmMyV04wcEJsdy1kSHBFMXJmcjMyc1FTNXFZSXVMZXB3elRhdnVHb1VIU25GM00tWFk4R0hWV0k4QU5sZWN3bGcyN29fU21VZTdxaldpbms3ZVlBS05OMGwzanVzZVl3S1NUei1HYlotYXZQeTZYTERfRDZDLXdtb1AxeGtJQjlGOU1tTktMZ1JZUF82b1gyd0k?oc=5", "source_name": "Karyopharm", "published_at": "2024-05-08T07:00:00+00:00", "published_display": "08 May 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "KPTI5813817 Bond Risk Profile", "summary": "This article provides a bond risk profile for Karyopharm Therapeutics Inc.'s 6.0% bond, KPTI5813817, due May 13, 2029. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliability. ", "url": "https://www.tradingview.com/symbols/FINRA-KPTI5813817/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-14T03:11:42", "published_display": "14 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI5813817 Bond Profile \u2014 Key Metrics", "summary": "This article provides a bond profile for Karyopharm Therapeutics Inc.'s KPTI5813817 bond, detailing key metrics such as a 6.0% coupon rate and a May 13, 2029 maturity date. The company, founded in 2008, is a commercial-stage pharmaceutical company focused on cancer and other dise", "url": "https://www.tradingview.com/symbols/FINRA-KPTI5813817/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-13T21:42:03", "published_display": "13 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE40Z3RWQmc1X0ZQMzRVQnJycEYxTmRSdkFwXzUxcEdja3VrM1d4ODBBSTVJRjFmRDJVcGtCMHZJQzdMSUVqWnVBTlUyZUoxaGJfVzM0VTE2emJCWmc?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:13:55+00:00", "published_display": "11 Jul 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16", "summary": "RBC Capital has reiterated its Buy rating for Karyopharm Therapeutics (KPTI.US), maintaining a target price of $16. This indicates the firm's continued positive outlook on the company's stock performance and valuation. The maintained ratings suggest that RBC Capital perceives ong", "url": "https://www.moomoo.com/news/post/72681903/rbc-capital-maintains-karyopharm-therapeutics-kptius-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-09T07:40:58", "published_display": "09 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Q2 2024 earnings summary", "summary": "Karyopharm Therapeutics (KPTI) reported a strong Q2 2024, achieving a net income of $23.8 million, a significant turnaround from a net loss in Q2 2023, primarily due to a non-cash gain on debt extinguishment. Total revenue grew to $42.8 million, driven by increased license and mi", "url": "https://quartr.com/events/karyopharm-therapeutics-inc-kpti-q2-2024_3PQWjohD", "source_name": "Quartr", "published_at": "2026-07-08T18:10:07", "published_display": "08 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Q4 2024 earnings summary", "summary": "Karyopharm Therapeutics (KPTI) reported total revenue of $145.2M in 2024, with U.S. XPOVIO net product revenue at $112.8M, and a reduced net loss of $76.4M. The company is advancing pivotal phase III clinical trials with key data readouts expected in 2025 and 2026, and anticipate", "url": "https://quartr.com/events/karyopharm-therapeutics-inc-kpti-q4-2024_3PQWjfnc", "source_name": "Quartr", "published_at": "2026-07-08T17:40:33", "published_display": "08 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Q1 2025 earnings summary", "summary": "Karyopharm Therapeutics released its Q1 2025 earnings summary, highlighting progress in its Phase 3 SENTRY trial for myelofibrosis, which passed futility analysis and is expected to complete enrollment by mid-2025 with top-line data anticipated late 2025/early 2026. Despite a dec", "url": "https://quartr.com/events/karyopharm-therapeutics-inc-kpti-q1-2025_3PQWf4fK", "source_name": "Quartr", "published_at": "2026-07-08T17:40:32", "published_display": "08 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics faces a data setback as investors weigh late-stage cancer pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPVHBkdWpxcWVVMnMzYU1ZM2tabEZ2ZXhSQ3hlcXJFYmtuNWR2WEdjMUJRZ2sxOHhSMkllVWdmd3Ziem95OHpuSFJ1bzlQTEpxMFhLUkJqZy1idkQtM0w0dFhjVUFlOFFIUFduRGZ4YS16Q08wX3hrNEk3S2JVaFdXUWF3VVlqVDk1dmZrUnJyR3NGRkM4TTVVcW1rcUxzOVJwcDl5WXNITlBNMmdsMDN2WFNjRktVYnVCcVU1NDVQanBNdWZkM2hPR2pSTWZ3Zw?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T19:37:26+00:00", "published_display": "07 Jul 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI - Karyopharm Therapeutics Inc Latest SEC Filings", "summary": "This page provides the latest SEC filings for Karyopharm Therapeutics Inc (KPTI), along with a comprehensive overview of its financial data, market performance metrics, insider transactions, and analyst recommendations. Key figures included are market capitalization, sales, incom", "url": "https://finviz.com/stock?t=KPTI&p=d&ty=lf&r=m6&page=30", "source_name": "Finviz", "published_at": "2026-07-06T16:42:39", "published_display": "06 Jul 2026 16:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Karyopharm Therapeutics Inc. announced it granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees on June 30, 2026. These RSU awards, made under the Company's 2022 Inducement Stock Incentive Plan, are material inducements for their employment as ", "url": "https://investors.karyopharm.com/2026-07-01-Karyopharm-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4", "source_name": "Karyopharm", "published_at": "2026-07-06T06:11:28", "published_display": "06 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm gives 4 new hires stock awards vesting over 3 years", "summary": "Karyopharm Therapeutics (Nasdaq: KPTI) granted 1,649 restricted stock units (RSUs) to four new employees on June 30, 2026, under its 2022 Inducement Stock Incentive Plan. These RSUs, designed to induce employment, will vest over three years, with 33 1/3% vesting annually, conting", "url": "https://www.stocktitan.net/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-gnqqzmakh8pq.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:09", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI - Karyopharm Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial snapshot of Karyopharm Therapeutics Inc (KPTI), including its stock performance, key financial metrics, and volatility data. It lists various ratios, growth rates, insider and institutional ownership, and analyst recommendations. The dat", "url": "https://finviz.com/stock?t=KPTI&p=d&r=m6&ty=ocv&ov=chain_date&e=2026-08-21", "source_name": "Finviz", "published_at": "2026-07-01T14:39:58", "published_display": "01 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI - Karyopharm Therapeutics Inc Dividends", "summary": "This article provides detailed financial and stock performance data for Karyopharm Therapeutics Inc. (KPTI). It includes various financial metrics such as market cap, income, sales, EPS, and insider ownership, alongside stock performance indicators over different periods. The dat", "url": "https://finviz.com/stock?t=KPTI&b=2&p=m&ty=dv", "source_name": "Finviz", "published_at": "2026-07-01T02:39:09", "published_display": "01 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark", "summary": "Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to the Russell Small Cap Comp Growth Benchmark, as announced by S&P Capital IQ. The company is a commercial-stage pharmaceutical firm focused on developing and commercializing drugs that inhibit nuclear export for cance", "url": "https://www.marketscreener.com/news/karyopharm-therapeutics-inc-nasdaqgs-kpti-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd81f623", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:40:24", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Index", "summary": "Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), a commercial-stage pharmaceutical company, has been added to the Russell 2000 Index. The company focuses on discovering, developing, and commercializing drugs targeting nuclear export for cancer treatment, with its lead asset XPOVIO (", "url": "https://www.marketscreener.com/news/karyopharm-therapeutics-inc-nasdaqgs-kpti-added-to-russell-2000-index-ce7f5fdfda8dfe26", "source_name": "marketscreener.com", "published_at": "2026-06-29T18:40:24", "published_display": "29 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Growth Benchmark", "summary": "Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to several Russell indices, including the Russell 2000 Growth Benchmark, Russell Small Cap Comp Growth Benchmark, Russell 2500 Growth Benchmark, and Russell 2000 Index. This inclusion follows a period of news regarding ", "url": "https://www.marketscreener.com/news/karyopharm-therapeutics-inc-nasdaqgs-kpti-added-to-russell-2000-growth-benchmark-ce7f5fdede8fff2c", "source_name": "marketscreener.com", "published_at": "2026-06-29T10:40:24", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000E Index", "summary": "Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to the Russell 3000E Index. The company is a commercial-stage pharmaceutical firm focused on developing drugs against nuclear export for cancer treatment. Its lead asset, XPOVIO (selinexor), is used for multiple myeloma", "url": "https://www.marketscreener.com/news/karyopharm-therapeutics-inc-nasdaqgs-kpti-added-to-russell-3000e-index-ce7f5fdedd8ff22d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:41:41", "published_display": "29 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Karyopharm Therapeutics Inc. \u2013 NASDAQ:KPTI", "summary": "This article provides access to the enterprise value to EBITDA forward data for Karyopharm Therapeutics Inc. (NASDAQ: KPTI) on the TradingView platform. It highlights the company's financial overview within the pharmaceuticals sector, emphasizing data sources and intellectual pro", "url": "https://www.tradingview.com/symbols/NASDAQ-KPTI/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:39:20", "published_display": "28 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Karyopharm Therapeutics Inc. \u2013 NASDAQ:KPTI", "summary": "This article provides the \"Price to sales forward\" metric for Karyopharm Therapeutics Inc. (NASDAQ: KPTI). It is a short piece that simply presents this specific financial data point without further analysis or commentary. The content indicates \"No trades\" at the time of viewing,", "url": "https://www.tradingview.com/symbols/NASDAQ-KPTI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:09:24", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics, Inc. Actuals & Estimates (NASDAQ:KPTI)", "summary": "This article provides an overview of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) stock, including its current price, market capitalization, and analyst forecasts. It details historical stock performance, earnings per share, and revenue figures, along with upcoming earnings dates.", "url": "https://www.tradingview.com/symbols/NASDAQ-KPTI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:35", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25K0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Karyopharm Therapeutics, Inc. (25K0) stock, including analyst price targets and ratings. It also offers key financial metrics such as EPS, revenue, net income, and EBITDA, along with frequently asked questions about the company's stock perform", "url": "https://www.tradingview.com/symbols/DUS-25K0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:35", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPTI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a comprehensive forecast for Karyopharm Therapeutics Inc. (KPTI) stock, including analyst price targets, historical performance, and financial metrics. It details the company's recent stock movements, earnings reports, revenue, market capitalization, and vol", "url": "https://www.tradingview.com/symbols/NASDAQ-KPTI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:35", "published_display": "25 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOd2NPYkRxak5DWF9XRUJzMHYyN09ES2NSd0Jmd0J2eG1iN3ltS0xDVkJGUkJEVjFKU3ZQLUVCbkJnTzFPU1JaSEVHblRKeEFlSTlGMFVLanExdFdrZS1zWEM1WE5kdU1mQXFjdl9NMEVCNGRCeE1ETnFIOHJDRmNLMEZ6V1VUQmxUWGtFUmNNOFVCTWNDb0FESm84NVIzdkNlNV96M1lDOA?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell", "summary": "Karyopharm Therapeutics receives a reiterated Sell rating due to ongoing clinical and commercial challenges with its drug selinexor (Xpovio). Stagnant Xpovio revenues of $115 million, coupled with toxicity issues and competition, undermine growth and adoption. Recent Phase 3 tria", "url": "https://seekingalpha.com/article/4916153-karyopharm-xpovio-revenue-stagnation-and-toxicity-concerns-justify-sell", "source_name": "Seeking Alpha", "published_at": "2026-06-18T20:39:56", "published_display": "18 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc (KPTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Karyopharm Therapeutics Inc (KPTI), highlighting its current price momentum score, support and resistance levels, and various technical indicators and moving averages. The analysis suggests that KPTI is suitable for range-bound swing ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kpti/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:56", "published_display": "18 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Karyopharm Therapeutics Inc (KPTI)'s shareholder structure, including its major individual shareholders and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type (e.g., Hedge Fund, Inves", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kpti/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:17", "published_display": "18 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Karyopharm Therapeutics Inc (KPTI). It indicates that KPTI has distributed $0.00 in dividends over the past five years and lists several upcoming merger-related stock splits scheduled for February 24, 2025. T", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kpti/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:17", "published_display": "18 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Karyopharm stock", "summary": "Cantor Fitzgerald has reiterated an Overweight rating on Karyopharm Therapeutics (NASDAQ:KPTI), following discussions with management about the potential of selinexor in endometrial cancer maintenance. The firm highlighted the unmet need in this area and how existing data de-risk", "url": "https://m.uk.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-overweight-on-karyopharm-stock-93CH-4719513?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-09T13:09:56", "published_display": "09 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPbUI3dlBnUTFtcTNZQTJ1LU81eUZQM1JvVVZEOVc3UjdFSnlrcXJDdkttNnJOQndpb3lyLXF0Vldyd2w3a2I1aUtubmxoV3A4RXVheGI5eDdjbjZ2aUVKTmt0SGJrWmVjYWF0VUhVOEJUX0VCajFvZjdqX1R4SkwzaVBtNmNVM3RRTnJtZTNHc1k0N0lyWURLd2FWNXU4NzV3R1lGNi04TEhMVmJrcHl6SzdrcGE?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Karyopharm Therapeutics Inc. announced an inducement grant of 1,200 restricted stock units (RSUs) to a new employee, effective May 31, 2026. This grant was made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. The RSUs will vest over three years, cont", "url": "https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302786006.html", "source_name": "PR Newswire", "published_at": "2026-06-05T06:09:11", "published_display": "05 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026", "summary": "Karyopharm Therapeutics Inc. announced it will host a virtual fireside chat on June 8, 2026, featuring its senior management and Dr. Robert Coleman, a key opinion leader in endometrial cancer. The webcast, organized by Cantor, will discuss the company's progress and the Phase 3 X", "url": "https://investors.karyopharm.com/2026-06-03-Karyopharm-to-Participate-in-Webcast-Featuring-Endometrial-Cancer-Key-Opinion-Leader-on-June-8,-2026", "source_name": "Karyopharm", "published_at": "2026-06-03T22:39:34", "published_display": "03 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology", "summary": "Karyopharm Therapeutics announced it will present results from its Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis at ASCO 2026, with simultaneous publication in the Journal of Clinical Oncology. The trial demonstrated a rapid and nearly doubled rate of spleen", "url": "https://www.prnewswire.com/news-releases/karyopharm-to-present-results-from-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-in-late-breaking-oral-presentation-at-asco-2026-with-simultaneous-publication-in-the-journal-of-clinical-oncology-302788575.html", "source_name": "PR Newswire", "published_at": "2026-06-03T04:10:02", "published_display": "03 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/karyopharm-report-data-phase-3-152117570.html", "source_name": "MT Newswires", "published_at": "2026-06-02T15:21:17+00:00", "published_display": "02 Jun 2026 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAJBVV95cUxOQ3h3RDNiUDktQ1ZjLWJELUNHT29TejdCUTdqY2FSWE9MRFUtWnBOOUx5eGhzeXlJNnU1S3B5MjZfcDRsV09zem8tei1GMVBZZTVJc09ndzhkN2NkQUUtZEZqVlo0amw3WXBWT2pEZXRQYWJ4UUl3cjFtQ2lWOFdUdzF3QnZCLWpfYkt2WlNNZnBqczZZc2RKb3RGaGNVQno3ZFZSdlppYlpOcnEzUEhlUUVselNqWnZtYzBmTXI2ckhxOXFOaG1iSVRDV25hLTlhUzhGS3VmeXd3YlE0QnNwaHllMUdTQmxIWlNUcERHLU5RQzlHaEF5ZGVJS3UyZEtsMVExT01iNWJxSF9ldElGd2Z1UW9oRjdibTZYdQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAJBVV95cUxPUG1iOVpDSXZGSm1vR3QtZjA2Yl9DeWYxekFZcWlZdmVaTTQ0ZllUQWdicVZueXVGLW5BZmRYbEtxR2R3T1o2WXFweVhmWDZzSEdtbnJ0S0djNVlpclJOV2MwVWI4TE9vM3lfa2xZQnB6dldxX2c3bnlhZ2dmQVR6ZkFvUjhVNkVjdFBnem5aZEFYNXRoaFVWWmdGdVhSQ1BtV2JGZmlSSjFDU1hxVlBhV055RF9LTjQ3WVU5Z0czZUVNTjFwbUlrTTlSQlVUcWp6SS1leE9HRjBDUllhRTlVdnNscmF6VEVlaTdpemR3cnlXV3M5djQtRkZnYXJBSm1RS3JDbTJfUUVlZHYyRU1LU0ptLVU1RXMtQlFReDZYV0RYRzVKLXJvRkpqZFhNbm5n?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Quarterly Loss Deepens Reinforcing Bearish Profitability Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQd0ppMWQ4d0JqcGplRV93OWlyUjFNY010cUxuQWpmUDJtSS1UZ1Rfa2RNWnkwRVZraGZMOFl4djI3VHM0N3pLNmdrb0FCWW9ONC0xc3dDaDJuQ0FSQ0Q5dGo5dDY2NFc2VGhUcWNIb2V5bXZxUmNVWTVlbGNUaEM2R201a0lYeU5UUS1mUTJJeEtYZ0hMVGZMdHhEZ3lEaWFvZFJlUjNBTEE0VDBpN0hWNXUyRk81UlJYeWhkbWdySzNvUk1qX2JRRFpncDQxeVBNNTVGanJuQVBlQy1vYXZSNk9sNHRUUmtOV2lIUVhn0gHzAUFVX3lxTE5OeURfdWhpQ3lEUDJ5Q3dBLWYyVUcxc0tIenVHMVA5SEdBNVRVdFhoUlg0R01BOEU5c3NJejExSFdDOHRDUHlDVEs0STdLYTBsdExHUml2QnZyU0pQbWNSY2tVcEgyWGo0R01qRVQxSnVtUDJfLVR4bER0aDVOb0dGV2s3cWxsd3c0VmhZN1pudV93c3p1ejZxamF0dFdfaFJxMk5WSnlkazZZajdoWFRhNWs4TGtqOVNaY1YyX2hSc19Xam1TbUlSbU8ydkVQZFFjcWk5TG5KWVQyZU1idFZvZVVORi0yb3lQMXpDbVY5bjUzTQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxQNHVSSm55NG1qaUVJT3lqVXlfV3dlZ25KMm5JYndWT3ZLRDlwNVlxSkhqV1BkSlhaNHpSSnM5MVR4V1NGckYwVFBWZ0xabTJ5OHBPTDhUZmhURGQxcFdXTV9UbF9WdmctQnE2bm9tQl9renY5RzJjRUl3ODc0TDlBdURkNHlRbXpPWFVOb2gtUTNfRDRLSFl0aVU0VXhaa01ILU1mTFdtUTVKSFVuQU8tM1N6ZUNIcnZHNVJYenZPdmYzajJ3UThyWExfUlZHYzBVRnVDMDR2ektLZzdVR0c5REQ0RmRQcnBHLU5rZDNCOFIzV2tiUDVvMXlzUEltT2NwUFcw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics stock (US48666T1097): Analyst target lifted as biotech eyes growth in XPOVIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOZUZaNXVHUl9PY3cxdnllMnctMXQ1Wm1UOVBtVG9PbGZNSUJjTDgwUVN0UWtXTXc0dERYOWJyc3A3cUdmLWlnMzNVdmVwSUl4U0JIa0Z5c2gzQTJqOUhId05KNVlFWDhhNVpsbFR6VVZyYWk2XzVoT21JTTd3VGJKNXRyOEhKV1A5RzVvU1J5eVpVSDZEQ19xcmJ4dC1uS2FXa3NzN2lMWTRLMVA4VFluV3JnLU5LNTE4WkxFR2R4M2gxeGhE?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxONVR2YnVXRlRiQmE5djRVcmFFc2hYdlNXb0ZiUDBsNHN6M1EtMDh1U2M3ZGZCQ1AwSnJ0eHhLM3NyUnl5a3BpdkZ4bVUwbi0zX3pRdGxPdzBhU1ljbFBxTEJQNzNiNFpSUlRaamJ3YjJKQXlyQzBsMVF1WjlTaXA0aXNxZEJVVTkxQUZNU28xNWZSelhSdGxhSW5Tb21ObUkyVW5pd2xOTEw?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxNaENpTi1uUXdmb0VQa05EZlRXclZKZHdZUjAyZ2hfWVVNTFAxMEd3dDBnWFlsTEZqa1ZZMTUzbnFDQ21VLTZoR3VHVnk4NFVKNlZWU1lPS2VGV3BhVkpIVEdMeDFYMU9hSllxeENQamF5UVZpQ01qMUhzOFl6YnZ6aVVQcU9sdHd2SHpHaWkwb2MwcU5nVDk1a3JlZDNXa3VjMWlWYXJYcWcyZGhjemo1MGhINms5T1dKZFIyUzRWYzFhMjUyZW5YZXVhajBuZG5rSng1aE5oZFg4Tk5KRVA2LVhwZVN4S3h3VWc1Z3dfM0I2X2htNWR6VmpjY1dkZ2VUSkF4VHhjanhOekhGVWxfZDJJdklKOUdMSWUzU1NRVl9KOFVUQ1VFZlFDbw?oc=5", "source_name": "Karyopharm", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces $30 Million Private Placement with RA Capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPWXltbXltM2tBbm1QLUpWZmpQYXB2LS0wb1RhXzlwRl9YY2ZPTnpidGpOXzI2R2FNRk5MdDE1RWJtTlBhM3dDb3dwdWR5UW5RbERUMjlOTU9oQ0E5eHdmRnRkOEd0Ymx0RTF4R21IWkt2cFd0cmZDVmk4VkNmY0ViT1Uwby1WMzU1SVpyYW5oakFSdTRlLWtJQWMzaUx6UFloNzc5WDdzM25scmlQbVYwZTVPREZnQlBjcFNRekVn?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNX3FGRVM2RFFhQnNhVDdaekNuS25WcjUyaHNINWo5aXo3T0xuYTRjTnI3VG5hZ1NHQW9lOWdoRXlwUDhRX0duSTRxbVlhYXVja1lhSFl2R3hKd3hwNklKdEpqazRvR1Vmd3NFTmlFeFZrYXNxUG5UZkJzY3pCdnp6NnVfZ0paRDVFWUx0VV9VT1cwaUM2emFIRUZ4MDN3U1hXNEdrWnpZbnpKR0haWWVDVHQ5akhCM01rc1E?oc=5", "source_name": "Market source", "published_at": "2026-03-22T07:00:00+00:00", "published_display": "22 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc. Common Stock (KPTI) Stock Price Today: $10.34", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1rTE1WT2ZMOXpWQTM0eGRBUEhMRGZFb2ozVlV5bTlibWlZelBqQ3hjNDFaM181eHRaa2czdVh3MkY5WC1hM0xrVkhLVjZkYXhHaTBoMUNQTQ?oc=5", "source_name": "Gotrade", "published_at": "2026-02-14T22:17:35+00:00", "published_display": "14 Feb 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQMmhCbGxTaHktZ3ZqUXlldl9NYm5OX2FnMUNnVzNTblc3MTJvSWFLMmwxaFowX2tjajNONnhjQThEX1RiZGpEQWZMVDJ6d3BYYWNnZVd2cEJfV3hwbFZjYWtlRGc5Y2w0anR0Qlgxand6TlNhRWtBbXN0a0xXb1FiaDZoRV9aOHY0TmtfenNB?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How New Price Targets Are Shaping The Story For Karyopharm Therapeutics (KPTI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPU3dWU2RDT1VzeFV2eFFHWVVTazJLNlo1ckRHUkJoT2V5VzdaMWl4RWUxazZRZXBkQzk0aDZsVlY5TTY1MW9YOHFxb0xlOUxGaFV0MFI5b180b1VoM096X2pJNDZwWHltUGVXZ2YteXk4UnRMMGkxUDhaTFM0d0RTTElSTkZMRnNYN3Bwdw?oc=5", "source_name": "Market source", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOVG1PaEJkRDNERnE3NG1IQnhmZlktNkZ0NExpeTd5dkx0bGpHaWJ4OHcxczR4bEF2b3R3SnBqb1BncWY1bzZMOW9KYnN4OEd4THBJek1vb3hJZTBPWVItZTVHU1hERjh2azQ3cHhuV1NTT1FoZHBtNTY3QjBIYjZma1lTSVgwOVNSNTFDMEZXXy1ub2ZsUm44QWE4OEs3em41VF9kR2ZJTVJTWmRpQ1ZBVzVmY1o3M09KeHZCc055ZTB2MmRDOXd2eE8wQkR2ZzN5ejh0Ng?oc=5", "source_name": "Karyopharm", "published_at": "2025-11-03T08:00:00+00:00", "published_display": "03 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOaHVpMGIyUFdmY1poRjVoVXVIdlBXTmVBUGdNZHBsMVRQV19PYnVsTzFkdy0ySHJVZlptcmRpVm5TRTBEcUNPcWV1Qm1sZkphNWYyd0lYeGs2SERvSERwbVN6bTNKYTZfdUZLS2JibGdUQUd5ZU5Odkk5bVhLc2ljYUMzSEtpSFJsX2l0aC1qMjByWTYyQ2szWkJfUzNVQ0dzVkQyaDF5WE1ERzhySU1WRm1fQ1hzdEw5WEtWMDdtZzVldHBoTTl3RE5wcVZWVk0?oc=5", "source_name": "Karyopharm", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxNRm11V3Q3MTlMTzR4blNHMmdNLUI5Z1ViVktnVHNoU1JsQ2swY0VmNTMtaEtzWWJZaDZtZXB6VUJrUklUQml2b1hjaW9xdXN6M1B4WnhNNkRiaU1DejNGbkNJSTFDVk1rWlU1VzVGbFRpR0V1WWVHclg0bG85czF5WWNDRzVCSTBjWXA5aGtkZ0VqZktPelFJT0M1NWlWY0pKRkJ0WkJzcElWWkxlYnpuMlZiOHpqY0N3N0FLV3RxSUF1N3FSdm96VGRYMGVpQ2hVZWV5S1hKakVqcUNNQ3ZzRVM1TmVqZEJxTkhROTdR0gHzAUFVX3lxTE1sTHRMSTJWSEdTYWtYVWxaUlZ5U2lqZUtaMjFwLWZYeXFCZk4wMUhqbUVxVF9VRm4yVFFWQ1l4VzZiSGVzQXdxbGEtRnd1QV9hNEYzczlaM05zVzN6MGEyYTZWd0JRUUdpWHNITjdrenh6Q1AyMUdSS3RNVjZ4NGtZWVlUR3VRZDlBUERjTjJCX0xKc2dVZHVDeV9JRzFjUVUxd0RJbl84WjBDblA2VTZ4LUU1Xy05T0k1dG41MDNJZlNGcXlETWFWU0ROVGdjZ2d6TVhMOFpTUG1odzdvRnpYb1ZjaklNNWlYdzBrY2luX2EyRQ?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-14T07:00:00+00:00", "published_display": "14 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQb1JnLW5xMk85WWoyaDlfZjFrYU1PcDhaeHV5cW91LWhwdm9BTkx6ZktyRURPQ3ZaUVhLSndHVFRhbGhwTUhYVGw0b1F4UXdCX3dWUUZuZ2Q0TVVKNEtIcl9jMzRvMWhmQnViaVZSZktvUEY2QWRFeHp1SklQT0ZsVFVTQkRhN3R5NGRFX01HcVo2NkxPWExORWt0WU1xSTV1RTZ0azM0MTRuNGhLZng1ZDdjekk1Z05TQTJiSTNlY1p0dw?oc=5", "source_name": "Karyopharm", "published_at": "2025-01-02T08:00:00+00:00", "published_display": "02 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowJBVV95cUxNRkVEMzNuWlgtbjdPVXVmUzBRVXpFSHl1bHBONXROc2Z4RW12Q0tEaXNCbEpXeHRfZy1oZ0RraVJVVF82QVE5V2o0R3MyWktyM2xhV2hiajdDd01CTVBCdUJNdFQ2YkJIMEYyb1VId1N2SVJBb1lGcnpRalhyODFZMDZpXzRRWTdqVjI0X2h5LThiNmMyV04wcEJsdy1kSHBFMXJmcjMyc1FTNXFZSXVMZXB3elRhdnVHb1VIU25GM00tWFk4R0hWV0k4QU5sZWN3bGcyN29fU21VZTdxaldpbms3ZVlBS05OMGwzanVzZVl3S1NUei1HYlotYXZQeTZYTERfRDZDLXdtb1AxeGtJQjlGOU1tTktMZ1JZUF82b1gyd0k?oc=5", "source_name": "Karyopharm", "published_at": "2024-05-08T07:00:00+00:00", "published_display": "08 May 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 61, "sentiment_summary": {"positive": 15, "negative": 4, "neutral": 42, "score": 54, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 10.45, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 4.75, "count": 8}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 10.34, "latest_week": "2026-07-10", "one_week_move": 7.7, "four_week_move": 8.8, "twelve_week_move": 20.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.994269, "market_dynamics_buy_signal": false, "relative_strength": 25.948497, "fair_value_gap": -6.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 41.6827, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.7% over one week, +8.8% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 8}, {"label": "Karyopharm", "count": 7}, {"label": "PR Newswire", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "Quartr", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "TradingKey", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 8}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.7% over one week, +8.8% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "KPTI5813817 Bond Risk Profile"}], "updated_at": "2026-07-16T00:21:15.554890+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}